Image courtesy of Abbott

Abbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity M System

Originally posted on Abbott.com

– Alinity m is Abbott’s new molecular lab system, which was approved by the U.S. FDA in March

– The Alinity m system is highly advanced and greatly improves speed and efficiency, running up to 1,080 tests in 24 hours

– Abbott is launching Alinity m to U.S. customers and will be making the SARS-CoV-2 test available for use under an Emergency Use Authorization

– This is Abbott’s fifth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic

Abbott announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the company’s molecular test for the novel coronavirus (COVID-19) for use on its new Alinity m molecular laboratory instrument. Abbott is in the process of launching the Alinity m system to U.S. customers.

The Alinity m system was cleared by the FDA for use with Abbott’s HCV (hepatitis C) assay in late March. Abbott is working with hospitals and health systems in the U.S. to install this new instrument, which will help keep up with the growing demand for testing.

“Molecular lab tests play a critical role in detecting the virus for COVID-19. As a leader in diagnostics, we are pushing forward to develop high-performing tests across our platforms to help combat this pandemic,” said Robert B. Ford, president and chief executive officer, Abbott. “As we continue to develop and improve our testing technologies, we want to ensure they are meeting the needs of our customers – and right now that means having reliable tests for COVID-19 on all of our diagnostic instruments.”

The Alinity m system is Abbott’s most advanced laboratory molecular instrument. It is an automated platform, which can run more tests in less time to give laboratories improved efficiency and flexibility when using the system. The Alinity m system is able to run up to 1,080 tests in 24 hours, and our m2000 RealTime system can run up to 480 tests in 24 hours.

With current systems, running different types of tests at the same time will slow down the time to results and/or volume throughput. Alinity m delivers true random access, allowing labs to run any test, any time for different types of infectious diseases while still providing results in less than two hours. This is especially critical during the COVID-19 pandemic when volume, speed and flexibility are needed.

 

 

Latest News

Facebook logo

Facebook Forced To Pay a Record $14-Million Settlement for Discriminating Against US Workers

October continues to be a month Facebook likely wishes it could forget. First came Frances Haugen, the whistleblower who explained in chilling detail how the site and its algorithms are designed to profit off what she called “the spread and amplification of hate, misinformation and political unrest.” Then there was…

United States Capitol Building

More Than 300 Black Congressional Staffers Decry Lack of Diversity on Capitol Hill; Challenge Lawmakers To ‘Do Better’

Regardless of which party is in power at any given time, people of color continue to be woefully underrepresented in not just elected office but also within support roles working for those lawmakers. And now, hundreds of these staffers are speaking out about what they call an “appalling” lack of…